Manipulating Sensory Neurons with Cannabinoids to Tackle Chronic Conditions
A patent has been filed for the use of cannabis therapies for the manipulation of ion channels in sensory neurons that contribute to chronic pain, peripheral neuropathy, urinary cystitis, asthma, and specific types of hearing loss.
FDA Grants Orphan Drug Designation for Another Cannabis-derived Drug
The designation has been given to Revive Therapeutics for the use of CBD in treating autoimmune hepatitis.
Improving Standards in the Cannabis Supply Chain
As the industry develops there comes a need to consistently produce and test for certain characteristics, like cannabinoid and terpene profiles, in order to achieve the desired results.
EVIO Labs Berkeley Announces ISO 17025 Accreditation
As the California cannabis industry evolves and state-mandated laboratory standards of operation prove vital, both clients and consumers will now have assurance that the results will be accurate and reliable.
FDA Approves Drug Containing a Cannabis-derived Compound for First Time
Epidiolex contains cannabidiol (CBD) and is the first FDA-approved drug that contains a purified drug substance derived from marijuana.
ASTM Proposes Standard for Labs Working with Cannabis
The standard will outline best lab practices, recommended certifications, various types of analyses, and the quality assurance functions for labs working with cannabis.
Cannabinoid-based R & D to Focus on Tackling the Opioid Crisis
Studies have already shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior.
Effects of Cannabigerol Revealed for the First Time
These findings reopen the discussion about the ability of other phytocannabinoids, whose mechanism of action was unknown, to bind directly to cannabinoid receptors as Δ 9-THC does.
Daily Cannabis Use on the Rise in American Adults
Significant increases in cannabis use among adults 65 and older defy perceptions that older adults do not use cannabis.
DEA Permits Further Cannabinoid-based Pharma Research
The research is focused on developing a drug that enables patients to benefit from the medicinal benefits of THC without experiencing its inherit psychoactive properties.
